This approach has unveiled that a noteworthy percentage of SVT individuals (about 15–17%) test positive for the JAK2 V617F mutation, even if they do not meet the diagnostic criteria outlined by the World Health Organization (WHO) for an MPN [41]. This evidence concerns the gene JAK2 and myeloproliferative disorder.